Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-pacific hepatitis C virus genotype 1 non-responders/relapsers

Figure 2 Sustained virological response by on-treatment response. A: SVR based on undetectable hepatitis C virus (HCV) RNA at week 4, 8 and 12 compared with detectable HCV RNA at the same time points; B: SVR in Asians compared with Caucasians when HCV RNA was undetectable at treatment week 4, 8 or 12 compared with those with detectable HCV RNA at the same time points. Significant differences are shown. Only significant differences are shown.